Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the netherlands

ADHD Attention Deficit and Hyperactivity Disorders

Volumn 2, Issue 4, 2010, Pages 213-220

  van den Ban, Els ^a,d   Souverein, Patrick C ^b   Swaab, Hanna ^c   van Engeland, Herman ^a   Egberts, Toine C G ^b,d   Heerdink, Eibert R ^b,d  

^a Institute for Mental Health Care   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Addition; Adolescent; Adult; Atomoxetine; Attention deficit hyperactivity disorder; Child; Continuation; Discontinuation; Extended release methylphenidate; Immediate release methylphenidate; Psychostimulant; Switching

Indexed keywords

ATOMOXETINE; LONG ACTING DRUG; METHYLPHENIDATE;

ADD ON THERAPY; ADOLESCENT; ADULT; AGE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED RELEASE FORMULATION; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EXTENDED RELEASE FORMULATION; FEMALE; GENDER; HUMAN; IMMEDIATE RELEASE FORMULATION; INFANT; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTPATIENT; PATIENT ATTITUDE; PRESCHOOL CHILD; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COMMUNITY PHARMACY SERVICES; DELAYED-ACTION PREPARATIONS; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; MALE; METHYLPHENIDATE; MIDDLE AGED; NETHERLANDS; PROPYLAMINES; SEX CHARACTERISTICS;

EID: 79960055676     PISSN: 18666116     EISSN: 18666647     Source Type: Journal    
DOI: 10.1007/s12402-010-0044-9     Document Type: Article

References (60)

1. Aanonsen N, Lensing M, Prietz R (2004) Utproevende behandling med snetralstimulerende legemidler tol vokse men hyperkinetisk forstyrrelse/ADHD. Ullevaal University Hospital, Oslo
2. American Academy of Child and Adolescent Psychiatry (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry 41(suppl 2):26S-49S
3. Angold A, Erkanli A, Egger HL, Costello EJ (2000). Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 39:975-984 (discussion 984-994)
4. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ (2006) Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population- based study. J Dev Behav Pediatr 27:1-10
5. Barkley R, Fischer M, Edelbrock C, Smallish L (1991) The adolescent outcome of hyperactive children diagnosed by research criteria-III. Mother-child interactions, family conflicts and maternal psychopathology. J Child Psychol Psychiatry 32(2):233-255
6. Barkley R, Guevremont D, Anastopoulos A, DuPaul G, Shelton T (1993) Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5- year follow-up survey. Pediatrics 92(2):212-218
7. Barkley RA, Murphy KR, Kwasnik D (1996) Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 98(6):1089-1095
8. Buitelaar J (2002) Epidemiological aspects: what have we learned over the last decade? In: Sandberg S (ed) Hyperactivity and attention disorders of childhood. Cambridge University Press, Cambridge, pp 30-64
9. Bussing R, Zima B, Mason D, Hou W, Wilson Garvan C, Forness S (2005) Use and persistence of pharmacotherapy for elementary school students with attention-deficit/hyperactivity disorder. J Child Adoles Psychopharmacol 15:78-87
10. Buurma H, Bouvy M, De Smet P, Floor-Schreudering A, Leufkens H, Egberts A (2008) Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 33:17-23
11. Capone N, McDonnel T (2006) Medication persistence among agents used to treat attention-deficit/hyperactivity disorder, diabetes, and elevated serum cholesterol. In: American Psychiatric Association 2006 annual meeting. American Psychiatric Association, Toronto
12. Castle L, Aubert R, Verbrugge R, Khalid M, Epstein R (2007) Trends in medication treatment for ADHD. J Atten Disord 10:335-342
13. Coghill D, Soutullo C, d'Aubuisson C, Preuss U, Lindback T, Silverberg M, Buitelaar J (2008) Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adoles Psychiatry Mental Health 2:31-46
14. de Ridder T, Bruffaerts R, Danckaerts M, Bonnewyn A, Demyttenaere K (2008) ADHD in de Belgische bevolking; een epidemiologische exploratieve studie. Tijdschrift voor Psychiatrie 8:499-508
15. DeBar LL, Lynch F, Powell J, Gale J (2003) Use of psychotropic agents in preschool children: associated symptoms, diagnoses, and health care services in a health maintenance organization. Arch Pediatrics Adoles Med 157:150-157
16. DiScala C, Lescohier I, Barthel M, Li G (1998) Injuries to children with attention deficit hyperactivity disorder. Pediatrics 102(6):1415-1421
17. Donker G, Groenhof F, van der Veen W (2005) Toenemend aantal voorschriften voor methylfenidaat in huisartsenpraktijken in Noordoost-Nederland, 1998-2003. Nederlands Tijdschrift voor Geneeskunde 149:1742-1747
18. DosReis S, Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PL (2005) Multiple psychotropic medication use for youths: a twostate comparison. J Child Adoles Psychopharmacol 15:68-77
19. Faber A, van den Jong de-Berg L, van den Berg van den P, Tobi H (2005) Psychotropic co-medication among stimulant-treated children in the Netherlands. J Child Adoles Psychopharmacol 15:38-43
20. Faraone S, Biederman J, Mick E (2006) The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow up studies. Psychol Med 36:159-165
21. Fischer M, Barkley R, Edelbrock C, Smallish L (1990) The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol 58(5):580-588
22. Gagnon B, Low G, Schreyer G (2005) Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 30:100-107
23. Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS (2008) National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/ hyperactivity disorder in Taiwan. J Clin Psychiatry 69:131-140 http://www.keele.ac.uk/schools/pharm/MTRAC/ProductInfo/verdicts/A/ATOMOX ETI E.PDF
24. Hugtenburg J, Heerdink E, Egberts A (2005) Increased psychotropic drug consumption by children in the Netherlands during 1995-2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol 60:377-379
25. Kessler R, Adler L, Ames M, Barkley R, Birnbaum H, Greenberg P, Johnston J, Spencer T, Ustun T (2005) The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 47:565-572
26. Kooij J (2003) ADHD bij volwassenen. Inleiding in diagnostiek en behandeling. ADHD in adults. Introduction and treatment. Swets & Zeitlinger Publishers, Lisse
27. Lage M, Hwang P (2004) Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adoles Psychopharmacol 14:575-581
28. Layton D, Souverein P, Heerdink E, Shakir S, Egberts A (2008) Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users. A cohort study using pharmacy dispensing data in the Netherlands. Drug Safety 31:143-158
29. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC (2001) Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. J Am Med Assoc 285(1):60-66
30. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M (1993) Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50:565-576
31. Marcus S, Wan G, Kemner J, Olfson M (2005) Continuity of methylphenidate treatment for attention deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 159:572-578
32. Miller A, Lalonde C, McGrail K, Armstrong R (2001) Prescription of methylphenidate to children and youth, 1990-1996. Can Med Assoc 165:1489-1494
33. Mitchell B, Carleton B, Smith A, Prosser R, Brownell M, Kozyrskyj A (2008) Trends in psychostimulant and antidepressant use by children in 2 canadian provinces. La Revue de Psychiatry 53:152-159
34. Multidisciplinaire Richtlijn ADHD bij kinderen en jeugdigen (2005) Richtlijn voor diagnostiek en behandeling van ADHD bij kinderen en jeugdigen (Multidisciplinairy Guideline for diagnosis and treatment of ADHD of children and adolescents). Trimbos Instituut, Utrecht
35. Murphy K, Barkley R (1996) Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: Implications for clinical diagnosis. J Atten Disord 3:147-161
36. Olfson M, Marcus M, Zhang H, Wan G (2007): Continuity in methylphenidate treatment of adults with attention-deficit/ hyperactivity disorder. J Manag Care Pharmacy 13:570-577
37. Pauw R, Dieleman H, de Vogel de E, Eussen M (2008) Retrospectief, observationeel onderzoek naar switchen en stoppen van ADHDmedicatie. Pharmaceutisch Weekblad, Wetenschappelijk Platform 2:183-187
38. Pohl GM, Van Brunt DL, Ye W, Stoops WW, Johnston JA (2009) A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res 8:95-103
39. Preen DB, Calver J, Sanfilippo FM, Bulsara M, Holman CD (2007) Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed. Aust N Z J Public Health 31:120-126
40. Prosser B, Reid R (2009) Changes in use of psychostimulant medication for ADHD in South Australia (1990-2006). Aust N Z J Psychiatry 43:340-347
41. Reid R, Hakendorf P, Prosser B (2002) Use of stimulant medication for ADHD in South Australia. J Am Acad Child Adoles Psychiatry 41:906-913
42. Robison L, Sclar D, Traer T, Galins R (1999) National trends in prevalence of attention-deficit/hyperactivity disorder and the prescription of methylphenidate among school-age children: 1990-1995. Clin Pediatr 38:209-217
43. Robison L, Sclar D, Skaer T (2005) Trends in ADHD and stimulant use among adults: 1995-2002. Psychiatr Serv 56:1497
44. Safer DJ, Krager JM (1994) The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools. Pediatrics 94:462-464
45. Scheffler R, Hinshaw S, Modrek S, Levine P (2007) The global market for ADHD medications. Health Aff 26:450-457
46. Schirm E, Tobi H, Zito J, van den Jong de-Berg L (2001) Psychotropic medication in children: a study from the Netherlands. Pediatrics 108:E25-E29
47. Sobanski E, Sabljic D, Alm B, Skopp G, Kettler N, Mattern R, Strohbeck-Kühner P (2008a) Driving-related risks and impact of methylphenidate treatment on driving in adults with attentiondeficit/hyperactivity disorder (ADHD). J Neural Trans 115:347-356
48. Sobanski E, Brüggemann D Alm B, Kern S, Philipsen A, Schmalzried H, Hesslinger B, Waschkowski H, Rietschel M (2008b) Subtype differences in adults with attention-deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment. Eur Psychiatry 23:142-149
49. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S (2005) A large, doubleblind, randomized clinical trial of methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456-463
50. Ten Have M, de Graaf R, Dorsselaer S, Verdurmen J, Land van't H, Vollenbergh W, Ormel J (2006) Prevalentie van impulsstoornissen. Resultaten van the European Study of Epidemiology of Mental Disorders (ESEMeD).
51. Trimbos Instituut, Utrecht Thompson J, Varley C, McClellan J, Hilt R, Lee T, Kwan A, Lee T, Trupin E (2009) Second opinions improve ADHD prescribing in a medicaid-insured community population. J Am Acad Child Adoles Psychiatry 48:740-748
52. Trip A, Visser S, Kalverdijk L, de Jong-van den Berg L (2009) Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 67:466-468
53. van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T (2010) Trends in incidence and characteristics of children, adolescents and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006. J Child Adoles Psychopharmacol 20:55-61
54. Vinker S, Vinker R, Elhayany A (2006) Prevalence of methylphenidate use among Israeli children: 1998-2004. Clin Drug Invest 26:161-167
55. Vitiello B (2008) An international perspective on pediatric psychopharmacology. Int Rev Psychiatry 20:121-126
56. Wilens TE (2004) Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 27:283-301
57. Winterstein A, Gerhard T, Shuster J, Zito J, Johnson M (2008) Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in medicaid database. Ann Pharmacother 42:24-31
58. Zito J, Safer D, dosReis S, Gardner J, Boles M, Lynch F (2000) Trends in prescribing of psychotropic medications to preschoolers. J Am Med Assoc 283:1025-1030
59. Zito J, Safer D, Satish Valluri M, Gardner J, Korelitz J, Mattison D (2007) Psychotherapeutic medication prevalence in medicaidinsured preschoolers. J Child Adoles Psychopharmacol 17:195-203
60. Zito JM, Safer DJ, Berg LT, Janhsen K, Fegert JM, Gardner JF, Glaeske G, Valluri SC (2008) A three-country comparison of psychotropic medication prevalence in youth. Child Adoles Psychiatry Mental Health 25:26-34